Mergers & Acquisitions Mergers & Acquisitions

Illumina next-generation sequencing critical for long-term plan, Exact Sciences CEO says at US FTC trial on Illumina-Grail deal

By Jenna Ebersole
  • 02 Sep 2021 17:39
  • 21 Oct 2021 05:31
Illumina's gene sequencing technology is so essential to the long-term plan of Exact Sciences that Chief Executive Officer Kevin Conroy has personally involved himself in supply contract negotiations over the matter, the CEO told a US Federal Trade Commission court today.
Conroy said he didn't get involved in the Illumina

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News